Вакцина bacTRL-Spike
Международное непатентованное наименование
Вакцина bacTRL-Spike
Торговое наименование
-
Производитель, страна
Symvivo Corporation, Canada
Лекарственная форма
oral vaccine
Механизм действия
Bifidobacteria monovalent SARS-CoV-2 DNA oral vaccine for prevention of COVID-19.
Each oral dose of bacTRL-Spike contains bacterial medium with either 1 billion (Group 1A), 3 billion (Group 2A) or 10 billion (Group 3A) colony-forming-units of live Bifidobacterium longum, which has been engineered to deliver plasmids containing synthetic DNA encoding spike protein from SARS-CoV-2.
Публикации COVID-19
Nicolas Vabret, Graham J.Britton, et al. Immunology of COVID-19: current state of the science. Immunity. 6 May 2020. DOI: 10.1016/j.immuni.2020.05.002.
Клинические исследования
1.
Название протокола
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability and Immunogenicity of the bacTRL-Spike Oral Candidate Vaccine for the Prevention of COVID-19 in Healthy Adults
Дата начала и окончания КИ
April 30, 2020 - December 31, 2021
Название организации, проводящей КИ
Symvivo Corporation
Страны
Canada
Фаза
I
Кол-во пациентов
84